Key Highlights
● Five patients with generalized myasthenia gravis were retreated with Descartes-08 at a median of 16.6 months after initial treatment.
● At Month 12, mean reductions were 6.6 points on MG-ADL and 15 points on MGC, with no serious adverse events.
● All five patients achieved clinically meaningful reductions on both measures, and four maintained the MG-ADL reduction through Month 12.
● Topline data from the Phase 3 AURORA trial are expected in the first quarter of 2027.
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) reported data on five patients with generalized myasthenia gravis who were retreated with its investigational cell therapy Descartes-08 after their symptoms returned. In a press release furnished with a Form 8-K on September 29, 2026, the company said the patients, who were retreated at a median of 16.6 months after finishing their initial course of treatment, showed mean reductions of 6.6 points on the MG-ADL scale and 15 points on the MGC scale at Month 12 after retreatment, with no serious adverse events. The company also said topline data from its Phase 3 AURORA trial are expected in the first quarter of 2027.
The Retreatment Data
The five patients had taken part in the Phase 2 portion of the company's earlier trials and were retreated after symptoms recurred. They had an average of 13 years of disease and extensive prior treatment histories, according to the release. Retreatment mirrored the initial course: six once-weekly infusions of Descartes-08.
At 12 months after retreatment, the mean reduction from baseline was 6.6 points (plus or minus 4.2) on MG-ADL, a patient-reported measure of daily activities, and 15 points (plus or minus 6.2) on MGC, a composite scale that combines clinician-assessed and patient-reported items. All five patients achieved clinically meaningful reductions on both measures, defined in the release as at least 3 points on MGC and at least 2 points on MG-ADL, and four of the five maintained a clinically meaningful MG-ADL reduction through Month 12.
On safety, the release states that no serious adverse events occurred during retreatment. It also reports no cytokine release syndrome, no immune effector cell-associated neurotoxicity syndrome, no cytopenias and no hypogammaglobulinemia. Adverse events were described as transient and mild, and the company said no new safety signals emerged compared with previously reported data. With only five patients, the data come from a small case series rather than a controlled comparison.
The Presentation and the Therapy
The data were presented on September 29, 2026 by Dr. James F. Howard Jr., a professor of neurology at the University of North Carolina School of Medicine and a Phase 2b trial investigator. The venue was the Myasthenia Gravis Foundation of America Scientific Session, held during the annual meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine in Orlando, Florida.
Descartes-08 is described as an autologous anti-BCMA CAR-T cell therapy made with mRNA rather than DNA, which the company says eliminates the risk of genomic integration. The release says it does not require lymphodepleting chemotherapy before infusion and can be given in an outpatient setting. It holds Orphan Drug and Regenerative Medicine Advanced Therapy designations for myasthenia gravis and a Rare Pediatric Disease designation for juvenile dermatomyositis.
Chief Executive Officer Carsten Brunn, Ph.D., is quoted as saying that the therapy "is being developed with the goal of providing sustained clinical benefit following a finite course of treatment." Dr. Howard is quoted as saying that "there remains a significant unmet need for patients suffering from MG today."
Descartes-08 Retreatment Sets Up AURORA Readout
The company's Phase 3 AURORA trial in generalized myasthenia gravis is expected to report topline data in the first quarter of 2027, with a Biologics License Application filing anticipated in mid-2027. The release says the FDA gave written agreement under the Special Protocol Assessment process that the overall Phase 3 design is acceptable to support a future application, contingent on trial outcomes. That agreement is not an approval and does not guarantee a result.
Cartesian also lists a Phase 2 trial in myositis (TRITON) and a Phase 1/2 trial in pediatric autoimmune diseases (HELIOS). The filing was made under Items 7.01 and 8.01.






Please wait processing your request...